レミブルチニブの市場規模、予測、新薬の考察（2032年）

薬剤のサマリー

レミブルチニブ（LOU064）は、B細胞やミクログリアなどの特定の免疫細胞の炎症活性に重要な役割を果たすブルトン型チロシンキナーゼ（BTK）酵素を強力かつ選択的に阻害する経口治療薬です。レミブルチニブは、肥満細胞や好塩基球のIgE架橋によって誘発される脱顆粒や、特発性および誘発性の慢性蕁麻疹患者の血清中に存在する因子によって誘発される活性化を阻害します。

当レポートでは、主要7市場（米国、ドイツ、フランス、イタリア、スペイン、英国、日本）における慢性特発性蕁麻疹（CSU）向けレミブルチニブについて調査分析し、市場規模の予測や、作用機序、用法と用量、研究開発活動などの情報を提供しています。

目次

第1章 レポートのイントロダクション

第2章 慢性特発性蕁麻疹（CSU）におけるレミブルチニブの概要

• 製品詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• その他の開発活動
• 製品のプロファイル

第3章 競合情勢（上市済みの治療法）

第4章 競合情勢（後期段階の新治療法）

第5章 レミブルチニブ市場の評価

• 慢性特発性蕁麻疹（CSU）におけるレミブルチニブの市場見通し
• 主要7市場の分析
  • 主要7市場の慢性特発性蕁麻疹（CSU）向けレミブルチニブの市場規模
• 市場の分析：国別
  • 米国の慢性特発性蕁麻疹（CSU）向けレミブルチニブの市場規模
  • ドイツの慢性特発性蕁麻疹（CSU）向けレミブルチニブの市場規模
  • 英国の慢性特発性蕁麻疹（CSU）向けレミブルチニブの市場規模

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: Remibrutinib, Clinical Trial Description, 2023
• Table 2: Remibrutinib, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Emerging Therapies)
• Table 5: Remibrutinib Market Size in the 7MM, in USD million (2019-2032)
• Table 6: Remibrutinib Market Size in the US, in USD million (2019-2032)
• Table 7: Remibrutinib Market Size in Germany, in USD million (2019-2032)
• Table 8: Remibrutinib Market Size in France, in USD million (2019-2032)
• Table 9: Remibrutinib Market Size in Italy, in USD million (2019-2032)
• Table 10: Remibrutinib Market Size in Spain, in USD million (2019-2032)
• Table 11: Remibrutinib Market Size in the UK, in USD million (2019-2032)
• Table 12: Remibrutinib Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: Remibrutinib Market Size in the 7MM, USD million (2019-2032)
• Figure 2: Remibrutinib Market Size in the United States, USD million (2019-2032)
• Figure 3: Remibrutinib Market Size in Germany, USD million (2019-2032)
• Figure 4: Remibrutinib Market Size in France, USD million (2019-2032)
• Figure 5: Remibrutinib Market Size in Italy, USD million (2019-2032)
• Figure 6: Remibrutinib Market Size in Spain, USD million (2019-2032)
• Figure 7: Remibrutinib Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: Remibrutinib Market Size in Japan, USD million (2019-2032)

"Remibrutinib Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about Remibrutinib for Chronic Spontaneous Urticaria (CSU) in the seven major markets. A detailed picture of the Remibrutinib for CSU in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the Remibrutinib for CSU. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the Remibrutinib market forecast analysis for CSU in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in CSU.

Drug Summary:

Remibrutinib (LOU064) is an oral treatment that potently and selectively inhibits Bruton's tyrosine kinase (BTK) enzyme, which plays a critical role in the inflammatory activity of certain immune cells such as B cells and microglia. Remibrutinib inhibits degranulation induced by IgE cross-linking in mast cells and basophils and the activation triggered by factors present in the sera of spontaneous and inducible chronic urticaria patients.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the Remibrutinib description, mechanism of action, dosage and administration, research and development activities in Chronic Spontaneous Urticaria (CSU).
• Elaborated details on Remibrutinib regulatory milestones and other development activities have been provided in this report.
• The report also highlights the Remibrutinib research and development activities in CSU across the United States, Europe, and Japan.
• The report also covers the patents information with expiry timeline around Remibrutinib.
• The report contains forecasted sales of Remibrutinib for CSU till 2032.
• Comprehensive coverage of the late-stage emerging therapies for CSU.
• The report also features the SWOT analysis with analyst views for Remibrutinib in CSU.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Remibrutinib Analytical Perspective by DelveInsight

• In-depth Remibrutinib Market Assessment

This report provides a detailed market assessment of Remibrutinib for Chronic Spontaneous Urticaria (CSU) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2025 to 2032.

• Remibrutinib Clinical Assessment

The report provides the clinical trials information of Remibrutinib for Chronic Spontaneous Urticaria (CSU) covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Chronic Spontaneous Urticaria (CSU) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Remibrutinib dominance.
• Other emerging products for CSU are expected to give tough market competition to Remibrutinib and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Remibrutinib in CSU.
• Our in-depth analysis of the forecasted sales data of Remibrutinib from 2025 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Remibrutinib in CSU.

Key Questions:

• What is the product type, route of administration and mechanism of action of Remibrutinib?
• What is the clinical trial status of the study related to Remibrutinib in Chronic Spontaneous Urticaria (CSU) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Remibrutinib development?
• What are the key designations that have been granted to Remibrutinib for CSU?
• What is the forecasted market scenario of Remibrutinib for CSU?
• What are the forecasted sales of Remibrutinib in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to Remibrutinib for CSU?
• Which are the late-stage emerging therapies under development for the treatment of CSU?

Table of Contents

1. Report Introduction

2. Remibrutinib Overview in Chronic Spontaneous Urticaria (CSU)

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. Remibrutinib Market Assessment

• 5.1. Market Outlook of Remibrutinib in Chronic Spontaneous Urticaria (CSU)
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of Remibrutinib in the 7MM for Chronic Spontaneous Urticaria (CSU)
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of Remibrutinib in the United States for Chronic Spontaneous Urticaria (CSU)
  • 5.3.2. Market Size of Remibrutinib in Germany for Chronic Spontaneous Urticaria (CSU)
  • 5.3.3. Market Size of Remibrutinib in France for Chronic Spontaneous Urticaria (CSU)
  • 5.3.4. Market Size of Remibrutinib in Italy for Chronic Spontaneous Urticaria (CSU)
  • 5.3.5. Market Size of Remibrutinib in Spain for Chronic Spontaneous Urticaria (CSU)
  • 5.3.6. Market Size of Remibrutinib in the United Kingdom for Chronic Spontaneous Urticaria (CSU)
  • 5.3.7. Market Size of Remibrutinib in Japan for Chronic Spontaneous Urticaria (CSU)

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options